Adimet

Quick links to important sections

Adimet

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adimet

What is Adimet? Overview

The information provided here defines the identity and pharmacological classification of Adimet (Metformin Hydrochloride) and its general therapeutic purpose.

Quick Facts Description
Active Ingredient Metformin Hydrochloride
Pharmacological Class Biguanide (Antidiabetic Agent)
Form Oral tablet (Standard and Extended-Release)
Route of Administration Oral
Origin Synthetic
Common Purpose Blood sugar regulation

Adimet: Classification and Core Active Ingredient

Adimet is a commercial, prescription-only preparation containing the globally recognized active substance Metformin Hydrochloride (INN). The medication is classified as a synthetic antidiabetic agent and belongs definitively to the Biguanide pharmacological class. This classification is clinically recognized for its distinct action profile. Unlike certain other antidiabetic agents, Biguanides are recognized for their role in targeting key metabolic processes.

Metformin is established as a key treatment for its primary indication, with a well-established history and efficacy. This fact indicates that the medicine is a widely accepted and foundational option for managing the condition.

General Purpose and Forms of Adimet

The general purpose of Adimet is to help the body regulate high blood sugar levels, reflecting its essential antihyperglycemic function. As a monotherapy preparation, Adimet contains only the single active compound. It is available as an oral dosage form, commonly presented as a standard tablet or a film-coated tablet. It is also frequently manufactured as an extended-release (XR) tablet, which is designed to optimize patient experience by facilitating absorption over an extended duration.

Metformin's primary action is to lower the elevated amount of glucose circulating in the blood. This action provides the patient with the systemic benefit of maintaining necessary metabolic stability, supporting a neutral use scenario focused on long-term metabolic control.

What side effects are possible with Adimet?

Possible Side Effects and Safety Information

The safety profile of Adimet (Metformin Hydrochloride) is documented by regulatory agencies and organized by the frequency and physiological system affected. The most frequently observed adverse reactions, classified as Very Common (occurring in ge 1/10 patients), are gastrointestinal in nature. These effects, which include diarrhoea, nausea, vomiting, abdominal pain, and loss of appetite, are noted in regulatory labels as occurring most often at the initiation of treatment.


Officially Documented Adverse Reactions by Frequency

Frequency Category Representative Adverse Reactions
Very Common Diarrhoea, Nausea, Vomiting, Abdominal pain
Common Taste disturbance
Very Rare Lactic Acidosis, Decreased Vitamin B12 absorption, Hepatitis, Skin reactions (Erythema, Urticaria)

The most serious risk documented in regulatory prescribing information is Lactic Acidosis, which is classified as a Very Rare adverse reaction and is the subject of a Boxed Warning in U.S. labeling due to its severity. This risk is highly dependent on the patient's renal function. Official labels contraindicate the use of Adimet in patients with severe renal impairment ( eGFR < 30 mL/ min/1.73 m^2).

Population and Exposure-Related Safety

The risk of Lactic Acidosis increases in individuals with conditions causing tissue hypoxia, such as decompensated heart failure or severe infection. Furthermore, official guidance requires temporary discontinuation of Adimet prior to and after radiological procedures involving iodinated contrast agents. For patients on long-term use, regulatory documentation notes the possibility of decreased Vitamin B12 absorption.

Overdose and Emergency Response

Overdose and when to seek help

The primary life-threatening outcome officially documented following Adimet (Metformin) overdosage is Lactic Acidosis, which regulatory documents classify as a medical emergency. This condition is severe and has been reported to be fatal in approximately 50% of cases.

Documented Manifestations and Emergency Action

Symptoms of Lactic Acidosis may be nonspecific and subtle in early presentation, including malaise, muscle aches (myalgias), respiratory distress, increasing sleepiness (somnolence), and nonspecific abdominal pain. Overdose frequently results in pronounced laboratory abnormalities, such as elevated blood lactate levels (generally exceeding 5 mmol/L) and decreased blood pH.

If Lactic Acidosis is suspected due to overdosage, the drug must be immediately discontinued, and patients are officially mandated to seek immediate medical attention for urgent treatment in a hospital setting.

Management and Risk Factors

Regulatory sources state that no specific antidote is available for Metformin overdose. Management is symptomatic and supportive, but the principal procedure described for treating severe acidosis and drug accumulation is prompt hemodialysis. The risk of this severe outcome is officially documented to increase significantly with concurrent conditions, particularly renal impairment, hepatic impairment, advanced age, and tissue hypoxia.

Therapeutic Uses of Adimet

Quick Facts

  • Condition: Type 2 Diabetes Mellitus
  • Therapeutic Focus: Supports the management of high blood sugar (glucose) levels.
  • Primary Use: Recommended as an initial treatment, alongside appropriate diet and physical activity.

Adimet (which contains Metformin Hydrochloride) is utilized for the management of high blood glucose levels associated with type 2 diabetes mellitus in adults. This medication is typically considered when modifications to diet and exercise alone do not result in adequate glycemic control.

Its therapeutic role is focused on helping the body to better manage blood sugar. It can be used as a stand-alone therapy (monotherapy) or in combination with other oral anti-diabetic agents or insulin to assist in achieving target blood sugar levels.

For certain adult patients who are overweight and exhibit risk factors such as impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), Adimet may also be considered to support a reduction in the risk or delay of the onset of type 2 diabetes mellitus.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Adimet — official regulatory information

Eligibility scope Statement
Populations for whom use is allowed (as stated in label): Adults and pediatric patients 10 years of age and older with Type 2 Diabetes Mellitus.
Populations for whom use is not recommended (if applicable): Children under 10 years of age; initiation is not recommended in patients with an eGFR between 30 and 45 mL/min/1.73 m^2.
Populations for whom use is contraindicated: Patients with Severe Renal Impairment (eGFR < 30 mL/min/1.73 m^2); Metabolic Acidosis (including Diabetic Ketoacidosis); Hepatic Impairment; conditions causing tissue hypoxia (e.g., recent severe heart failure, respiratory failure); and history of Hypersensitivity to Metformin.
Age-related eligibility rules: Approved for adults and children ge 10 years; safety not established in children < 10 years. Older adults require frequent renal function monitoring.
Condition-specific eligibility rules: Contraindicated in acute conditions that may alter renal function (e.g., severe infection, dehydration) and any condition predisposing to Lactic Acidosis.
Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy: Use only if clearly needed. Lactation/Breastfeeding: Use is not recommended or requires caution.
Eligibility-related restrictions: Temporary discontinuation is required for all patients undergoing iodinated contrast imaging procedures.

Resulting eligibility structure

Official regulatory documents define patient eligibility for Adimet primarily through absolute contraindications linked to severe organ dysfunction (specifically renal and hepatic impairment) and the presence of acute metabolic instability (acidosis or hypoxia). Eligibility is further governed by age limitations, permitting use in patients 10 years and older, and by mandating conditional use or temporary cessation during certain medical procedures (e.g., contrast imaging) or physiological states (e.g., pregnancy), as stated in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Adimet (Metformin)

The official interaction profile for Adimet is defined by regulatory guidelines that categorize constraints based on pharmacokinetic effects and procedural risks.

Category Description
Interacting Substances Cationic Drugs (e.g., Cimetidine, Ranolazine, Dolutegravir, Vandetanib); Other Glucose-Lowering Agents (Insulin, Sulfonylureas); Iodinated Contrast Agents; Alcohol (Ethanol).
Interaction Basis Inhibition of renal tubular secretion via Organic Cation Transporter 2 (OCT2) increases Adimet plasma concentration; Additive pharmacodynamic effects with other antidiabetic agents; Potentiation of lactate metabolism by alcohol.
Key Restrictions Iodinated Contrast Agents: Adimet must be temporarily discontinued at the time of, or prior to, the procedure and for 48 hours subsequent to the procedure. Alcohol: Excessive intake is officially restricted due to the heightened risk of lactic acidosis.
Population Notes Interaction-related risks of accumulation are heightened in patients with pre-existing renal impairment, as clearance depends heavily on stable kidney function.

Official Interaction Statements:

  • Co-administration with cationic drugs that inhibit renal clearance results in increased systemic exposure (AUC/Cmax) of Adimet.
  • Adimet combined with insulin or sulfonylureas results in a documented additive effect on glucose lowering.
  • Carbonic Anhydrase Inhibitors may also reduce Adimet clearance and increase systemic exposure.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents structure the product’s interaction profile around preventing drug accumulation through transporter-mediated effects and mitigating metabolic risks. The primary focus is on substances that affect the clearance pathway or those that synergistically increase the danger of lactic acidosis, requiring clear timing rules or use restrictions.

Mechanism of Action

️ Modulating Cellular Energy and Liver Output

Adimet initiates its action by targeting the core energy metabolism within liver cells, mildly inhibiting Mitochondrial Complex I. This cellular energy shift activates AMPK, which then suppresses the key enzymes responsible for hepatic gluconeogenesis. This mechanistic cascade directly limits the liver's production of new glucose, resulting in a reduction of systemic glucose output.


️ Enhancing Peripheral Glucose Clearance

The drug exerts a crucial secondary mechanism by enhancing the sensitivity of peripheral tissues (like muscle cells) to existing insulin signals. By promoting more efficient glucose uptake and utilization in these tissues, Adimet promotes cellular uptake and utilization of glucose. This domain is supplemented by a third mechanism that reduces the absorption of dietary glucose in the gastrointestinal tract, contributing to a less pronounced postprandial glucose excursion.


Mechanism Dependence and Constraints

Adimet operates strictly as a non-secretagogue, meaning its mechanism improves efficiency rather than forcing insulin release. This action is dependent on the presence of some functional endogenous insulin for the drug to enhance sensitivity and uptake. The mechanism does not operate by pushing glucose concentrations below the euglycemic range.

Dosage and Administration Information

How Adimet Is Used: Official Administration Guidelines

Adimet (Metformin Hydrochloride) is administered exclusively via the oral route. Its usage is governed by specific instructions concerning dosage, frequency, and timing to align with clinical standards.


Official Dosing Regimens and Frequency

Adimet is available in Immediate-Release (IR) and Extended-Release (XR) tablets, dictating two different frequency patterns. The IR tablet is typically initiated at 500 mg twice daily or 850 mg once daily and is taken in two or three divided doses per day. The dose is gradually titrated (increased) in small increments over several weeks until the usual adult maintenance range of 1500 mg to 2550 mg daily is reached.

For the XR form, treatment commonly begins at 500 mg or 1000 mg and is administered once daily. The maximum recommended daily dose for the XR tablet is generally 2000 mg.


Administration Conditions and Constraints

Adimet must always be taken with meals to ensure appropriate tolerability and absorption. The XR tablet is specifically recommended to be taken with the evening meal. For the XR tablet, a core instruction is to swallow the tablet whole; it must never be cut, crushed, dissolved, or chewed.

Standard protocols also specify use in certain populations: Pediatric patients (ages 10 and older) begin at 500 mg twice daily, with a maximum of 2000 mg daily. For older adults and patients with moderate renal impairment, a conservative initial and maintenance dose is required, and kidney function must be closely and frequently assessed. If a dose is missed, the user should not take a double dose and should instead resume with the next scheduled dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Adimet (Metformin)

The research landscape for Adimet (Metformin) is broad, primarily consisting of Randomized Controlled Trials (RCTs)—the highest standard of clinical research—and long-term follow-up studies that have monitored participants for decades. This section describes what research has examined, what the studies monitored, and what remains uncertain.

Evidence for Use in Managing Type 2 Diabetes Mellitus

Research exploring the use of Adimet for managing Type 2 Diabetes is supported by major, long-running studies, such as the UK Prospective Diabetes Study (UKPDS). These studies research examined how blood sugar markers change over time, specifically monitoring outcomes related to glycemic control by measuring HbA1c. The studies reported that when Adimet was observed in these adult populations, the HbA1c levels changed in patterns observed for the outcomes measured.

Long-term extensions were used to track major health events, including non-fatal myocardial infarction, stroke, and microvascular outcomes. What remains uncertain is the precise degree to which Adimet contributes to the long-term changes in cardiovascular events across all patient groups, as evidence quality varies across studies.

Evidence for Use in Delaying or Preventing Type 2 Diabetes Onset

Adimet was studied for its role in preventing or delaying the onset of Type 2 Diabetes in individuals at high risk, such as those with Impaired Glucose Tolerance (IGT). The research included large-scale, placebo-controlled RCTs like the Diabetes Prevention Program (DPP).

The research findings indicated that the incidence of Type 2 Diabetes diagnosis was different between the group receiving Adimet and the group receiving a placebo. This difference was observed in some studies and persisted throughout decades of follow-up. However, long-term effects are not fully established regarding cardiovascular outcomes in this setting, as follow-up data spanning up to 21 years reported that the incidence of major cardiovascular events did not show a statistical distinction between the Adimet group and the placebo group over that period.

Scientific Gaps and Areas of Research Uncertainty

Scientific assessments highlight several areas where certainty remains low. For example, some subgroup findings are uncertain, and direct comparative evidence is lacking against certain newer anti-diabetic agents for long-term cardiovascular outcomes. The data for certain groups (e.g., severe comorbid conditions) remain insufficient, and results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Adimet (FAQ)


Q: Why do some people say Adimet is difficult to start taking?

Official product information notes that the most frequently reported side effects, such as nausea, abdominal pain, and diarrhoea, are typically gastrointestinal in nature. Regulatory documents state that these issues occur most often during the initial phase of treatment when the medicine is started.


Q: Do I need to change my diet while taking Adimet?

Regulatory documents state that Adimet must be taken with meals to support appropriate tolerability and absorption. Patients are also advised to adhere to a recommended diet plan with an appropriate distribution of carbohydrate intake throughout the day to support overall treatment goals.


Q: Are there any specific foods that should be avoided with Adimet?

Official warnings specify that excessive alcohol intake is restricted because it significantly increases the risk of a serious, but rare, adverse reaction called lactic acidosis. Specific foods, apart from alcohol, are not typically listed with warnings against consumption in major regulatory documents.


Q: Can Adimet be taken with common over-the-counter pain relievers?

Regulatory documents list specific drug classes, known as cationic drugs, that may interact with Adimet by affecting how the kidneys clear the medicine from the body. However, common, general over-the-counter pain relievers are not explicitly listed in major regulatory interaction summaries.


Q: Why is Adimet sometimes prescribed along with other treatments?

Official guidelines state that Adimet may be used in combination with other agents, such as insulin, when the clinical goals for blood sugar management are not met with monotherapy. These combinations have a documented additive effect on lowering blood sugar.


Q: How long does Adimet stay in the body after the last dose?

Official pharmacokinetic data, which describes how the body processes the drug, indicates that Adimet has a plasma elimination half-life of approximately 6.2 hours. The half-life describes the time it takes for the drug concentration in the plasma to decrease by 50%.


Q: Are there different strengths of Adimet available?

Yes, official regulatory labeling indicates that Adimet tablets are manufactured and available in multiple dosage strengths. These commonly include 500 mg, 850 mg, and 1000 mg doses for both immediate-release and extended-release forms.


Q: What are the known potential risks when taking Adimet?

The most serious, though very rare, risk documented in regulatory labeling is lactic acidosis, which is a medical emergency. Additionally, official documents note that long-term use of the medicine may be associated with decreased absorption of Vitamin B12.


Q: Is Adimet the same as other medicines used for similar conditions?

No, Adimet is officially classified as belonging to the Biguanide pharmacological class, which has a distinct action profile. Regulatory descriptions state that this medicine is not chemically or pharmacologically related to other classes of oral blood sugar-lowering agents.


Q: How long does it usually take to notice effects from Adimet?

Official information indicates that Adimet typically begins to help lower blood sugar levels within the first week of treatment. However, it may take two to three months to observe the full effects on longer-term blood sugar markers, like HbA1c.


Q: Is there a generic version of Adimet available?

Yes, the active ingredient in Adimet, which is Metformin Hydrochloride, is listed in official drug directories. This means that multiple government-approved generic versions are widely available.


Q: Does Adimet cause stomach upset?

Official documentation lists diarrhoea, nausea, and vomiting as Very Common adverse reactions, meaning they occur in ge 1/10 patients. These effects are often covered under the general lay term 'stomach upset' and are most frequent when starting the medicine.


Q: How is Adimet different from a simple diet change?

Regulatory documents describe the drug's mechanism as a pharmacological action that primarily works by decreasing the liver’s production of new glucose and improving the body’s sensitivity to existing insulin. This is a systemic effect that is intended to complement, not replace, the effects of appropriate lifestyle changes.


Q: Is Adimet known to cause weight gain or weight loss?

Clinical study data reported in regulatory documents indicate that Adimet, when used alone, is generally associated with either a neutral effect on weight or a modest reduction in weight, according to clinical data.


Q: Can older adults typically use Adimet?

Official guidelines state that Adimet can be used by older adults. However, official guidance requires more frequent assessment of kidney function and conservative initial dosing to manage potential risk.


Q: Are headaches a potential side effect of Adimet?

Headaches are not listed in the 'Very Common' or 'Common' adverse reaction categories in official summaries of product characteristics. A healthcare professional can provide the full list of all documented potential side effects from the official prescribing information.


Q: Is it possible to be allergic to the ingredients in Adimet?

Official regulatory documents list a history of hypersensitivity, which is a form of allergic reaction, to the active substance (Metformin) as an absolute contraindication for use. This information is noted in the 'Contraindications' section of the label.


Q: Can Adimet impact my sleep schedule?

While sleep disturbances are not listed as a common side effect of the medicine, one of the non-specific symptoms of the serious but rare complication, lactic acidosis, is somnolence (drowsiness).


Q: Is Adimet ever prescribed for people who do not have the main condition it treats?

Official research evidence has been reported on the use of Adimet in individuals who are at high risk for developing the condition, such as those with Impaired Glucose Tolerance. In this context, it has been studied for its potential role in delaying or preventing the onset of the condition.


Q: Does Adimet affect my ability to drive or operate machinery?

The official product information states that Adimet, when used alone (monotherapy), does not typically cause low blood sugar, which is a major factor in impaired performance. It is therefore generally described as having no influence on the ability to drive or use machines.


Q: Do official documents mention any effects of Adimet on fertility?

Official labeling advises premenopausal females of the potential for an unintended pregnancy while using the drug, as it may cause ovulation in some women who were previously non-ovulatory.


Q: What age group is Adimet typically authorized for?

According to official regulatory documents, Adimet is authorized for use in adults and pediatric patients 10 years of age and older. It is indicated as an adjunct to diet and exercise to improve blood sugar control in these populations.


Q: Is Adimet a controlled substance?

No, official classifications from the U.S. Drug Enforcement Administration (DEA) and other regulatory bodies confirm that the active ingredient in Adimet, Metformin Hydrochloride, is Not a Controlled Drug.


Q: Are there any known issues with taking Adimet with antacids?

Official drug interaction summaries do not typically list common antacids as a major interaction requiring specific discontinuation or major adjustment. Regulatory attention is focused on drugs that may affect the medicine’s clearance or Vitamin B12 levels.


Q: How do regulatory agencies view the safety profile of Adimet?

Regulatory overviews often acknowledge that the active ingredient in Adimet is a well-established and foundational option for its primary indication. This view is supported by its extensive clinical research history and decades of long-term patient use data.


Q: Is Adimet generally considered a maintenance medicine?

Adimet is indicated as an adjunct to diet and exercise to improve blood sugar control. Its clinical use history and supporting studies indicate that it is often administered continuously and long-term to help achieve sustained management of blood sugar levels.

How should Adimet be stored and disposed of?

Storage and Disposal Requirements

Adimet (Metformin Hydrochloride) must be stored according to regulatory requirements to ensure its stability and effectiveness.

Requirement Official Condition
Temperature Controlled room temperature: 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection Store in a tightly closed container, protected from excessive moisture.
Child Safety Keep the medicine out of the reach and sight of children.

For disposal, unused or expired Adimet should be managed through an official drug take-back program when available. If no take-back program exists, the regulatory-approved method is to mix the tablets with an undesirable substance, such as dirt or used coffee grounds, seal the mixture in a container, and discard it in the household trash. Identifying information must be removed from the original container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adimet found in:

A-Z Index: